NewsRoom Articles - Page 114 of 154 - PsychedelicNewsWire (PNW)

FridayNov 20, 2020 2:30 pm

What’s the Position of the FDA on Psychedelics?

Lots of investors are picking interest in the psychedelics space, and one of the biggest questions on their mind has to do with the stance of the U.S. Food and Drug Administration (“FDA”) since this organization is the gatekeeper (so to speak) of any therapeutic product intended for human use. As you may already know, the FDA carefully reviews the data presented after studies are conducted. The purpose of this review is to establish whether the therapeutic compound or treatment modality is suitable for the condition targeted. Since the FDA is a federal government agency, it is obliged to bear…

ThursdayNov 19, 2020 3:15 pm

Legislator Calls for Psychedelic Decriminalization in California

Senator Scott Wiener of California plans to introduce a bill to decriminalize the possession of psilocybin (magic) mushrooms and other psychedelic substances. This, he says, is part of an agenda to decrease the failed war on drugs. He will introduce the bill in the legislature in 2021. Assembly members Sydney Kamlager and Evan Low worked on the bill with the senator. Wiener, who doesn’t indulge in psychedelics, stated in a recent interview that, while every substance has the potential to be harmful, psychedelic substances can and have been used safely. He added that psychedelics had significant medicinal uses. Psilocybin mushrooms…

ThursdayNov 19, 2020 2:32 pm

Pure Extracts Technologies Corp. (CSE: PULL) Begins Trading, Extraction Tolling Business Ramping Up

Pure Extracts Technologies trading on CSE under symbol PULL Company runs first oil extraction, distillation under new licenses PULL products highly desired by provincial dispensaries as consumers gravitate to FSO An emerging leader in extraction, Pure Extracts Technologies (CSE: PULL) began trading on the Canadian Securities Exchange (“CSE”) earlier this month under the symbol ‘PULL’. The plant-based extraction Company focuses on cannabis, hemp, and functional mushroom sectors and uses its proprietary CO2 extraction methodology to obtain full-spectrum oil (“FSO”) from cannabis and hemp biomass. “We are pleased to have listed on the Canadian Securities Exchange as a significant first step…

WednesdayNov 18, 2020 1:30 pm

Psychedelic Feminism on the Rise Globally

Cosmic Sister is an environmental collective made up of a growing number of talented women who are broadening the understanding of psychedelics as we know them. The group is doing this by developing and safeguarding valuable spiritual traditions, making art masterpieces, leading scientific research, composing books, publishing articles and presenting at psychedelic events. This feminist collective underpins emerging voices and female idea pioneers in the psychedelic field. The founder, Zoe Helene, invented the term “psychedelic feminism.” By pitching, supporting and promoting female speakers during more than half a decade, members of Cosmic Sister are helping shape the trajectory of global…

WednesdayNov 18, 2020 11:56 am

Pure Extracts Technologies Corp. (CSE: PULL) Now Trading on the Canadian Securities Exchange Under “PULL” Symbol

Pure Extracts trading on CSE under “PULL” symbol Pure Extracts cannabis and hemp industry verticals include toll processing, white labeling and developing its own private label of cannabis products Pure Extracts is entering the functional mushroom market Company’s CO2 extraction facility complies with European Union GMP standards - intends to seek EU GMP certification for exports to Europe Pure Extracts Technologies (CSE: PULL), a plant-based extraction company focused on the cannabis, hemp, and functional mushroom sectors, recently announced that the Company’s stock is now trading on the Canadian Securities Exchange (“CSE”) under the symbol “PULL”. “Our trading debut on the…

TuesdayNov 17, 2020 3:00 pm

Psychedelics Alter How Humans Recognize Facial Emotions

According to a systematic review that was reported in Therapeutic Advances in Psychopharmacology, psychedelic drugs such as LSD and mescaline decrease the recognition of negative facial expressions. Generally, the main facial expressions characterizing basic human emotions are happiness, sadness, surprise, disgust, fear and anger. The psychedelic substances do this by adjusting the amygdala’s activity, which is the region of the brain that drives a person’s flight or fight response. A postdoctoral fellow at the University of Sao Paulo, Rafael Guimarães dos Santos, who is the study’s author, explained that they’d been looking into the effects of ayahuasca on humans for…

MondayNov 16, 2020 3:15 pm

Opioid Drugs Approved in Last Two Decades Lack Sufficient Safety Assessments

Researchers from George Washington University and the Johns Hopkins Bloomberg School have discovered that the data used to approve opioid pain medications by the FDA from 1997 to 2018 depended on intermediate or short-term studies that largely didn’t sufficiently examine safety outcomes. The findings, which were obtained from a cross-sectional analysis, were reported in the “Annals of Internal Medicine.” The safety assessment and study details for every drug were examined. The investigators also amassed all 48 new drug applications for opioid goods that had been approved by the U.S. FDA for the treatment of chronic or acute pain. Among the…

FridayNov 13, 2020 3:24 pm

How Intravenous Ketamine Use Helps Manage and Treat Depression

Patients with treatment resistant depression tolerate ketamine therapy well, with many recording improvements in their depressive symptomatology score (QIDS-SR16) A chart review was carried out among patients with treatment resistant depression who were being treated at the Massachusetts General Hospital Intravenous Ketamine Clinic for Depression, on an outpatient basis. The study results were then published in the “Journal of Affective Disorders.” The researchers assessed the outcomes different outpatients experienced at the ketamine clinic between October 2018 and November 2019. The study involved 85 patients with treatment resistant depression. Before IV ketamine was administered during every visit, the severity of the…

FridayNov 13, 2020 10:46 am

Rritual Superfoods Gains Important USDA Organic Certification for Emerging Industry Superfood Elixirs

Plant-based superfood developer Rritual Superfoods Inc. gained certification from the USDA validating its organic product marketing recently, helping to establish the company’s premium functional food elixirs following their launch in September The initial three product line elixirs, shots and mixes promote wellness by blending select nutraceutical mushrooms with adaptogenic roots to promote the body’s immune and cognitive function, as well as to reduce stress Market analysts predict the overall functional foods industry will achieve revenues of $268 billion by 2027 Functional mushrooms are a still-emerging subsector within the industry, allowing Rritual opportunity to build a following from the ground floor…

ThursdayNov 12, 2020 3:30 pm

Patients with Depression Can Pay for Psychedelic Treatment in Netherlands

Recent discoveries have shown psychedelics to possess many benefits, some of which are known and others that are yet to be discovered. Among those that are known is the discovery that psilocybin can be used to treat depression. Psilocybin, sometimes dubbed magic mushrooms, also helps manage alcohol addiction. Research has shown that when psilocybin therapy is administered to a patient who has depression, it can take months for mild symptoms to reappear again. Over time however, if the therapy isn’t re-administered, the symptoms slowly return. Many governments across the globe have documented various illegal drugs, and in many countries, psychedelics…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000